---
title: "TC Biopharm (TCBP.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/TCBP.US.md"
symbol: "TCBP.US"
name: "TC Biopharm"
industry: "生物技術"
---

# TC Biopharm (TCBP.US)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |

## Company Profile

TC 生物制藥 (控股) 公司是一家臨床階段的生物制藥公司，從事基于其專有的同種異體γδT 細胞平台的新型免疫治療產品的開發。該公司由 Michael Leek 和 Angela Scott 于 2013 年創立，總部設在英國馬瑟韋爾。

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.01 | 66/603 | - | - | - |
| PB | 0.08 | 13/603 | 0.08 | 0.08 | 0.08 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 0.50 |
| Highest Target | 48.00 |
| Lowest Target | 48.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/TCBP.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/TCBP.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/TCBP.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.